WaveMan
WaveMan · Company
TCRT · Alaunos Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TCRT Alaunos Therapeutics (TCRT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001107421
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter

What the filings say about TCRT

Activist stakes (13D), 180 days
1 filing
Largest: 20.0% of the class

Alaunos Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Alaunos Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Vieser Jaime
Director
SELL
2025-01-03 SECtraded 2024-12-31
2,182
$4.4K
+11.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 29, 2022.
  • The trade is 8.2% of the 26,712 shares held after it.
  • No other insider sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Vieser Jaime sold about $4.4K of TCRT on Dec 31, 2024, the largest insider sale at the company since 2023; 13 funds added in the latest 13F quarter.
Vieser Jaime
Director
SELL
2025-01-03 SECtraded 2024-12-31
818
$1.6K
+11.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 29, 2022.
  • The trade is 3.2% of the 25,894 shares held after it.
  • No other insider sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Vieser Jaime sold about $1.6K of TCRT on Dec 31, 2024, the largest insider sale at the company since 2023; 13 funds added in the latest 13F quarter.
Boyle Kevin S. Sr.
Chief Executive Officer
SELL
2023-09-05 SECtraded 2023-09-01
68,014
$9.5K
-89.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 8.5% of the 798,236 shares held after it.
  • No other insider sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Boyle Kevin S. Sr. sold about $9.5K of TCRT on Sep 1, 2023, the largest insider sale at the company on our record; 13 funds added in the latest 13F quarter.
Postma Robert W
Director
BUY
2022-12-01 SECtraded 2022-11-29
750,000
$487.5K
-97.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 15.0% of the 5,000,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Postma Robert W bought about $487.5K of TCRT on Nov 29, 2022, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 13 funds added in the latest 13F quarter.
Vieser Jaime
Director
BUY
2022-12-01 SECtraded 2022-11-29
1,250,000
$812.5K
-97.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 1,250,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Vieser Jaime bought about $812.5K of TCRT on Nov 29, 2022, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 13 funds added in the latest 13F quarter.
5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
13 funds bought in last quarter
below 77% of Pharma & Biotech
Revenue
-50.0% year over year
below 80% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.8% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 81% of Pharma & Biotech
The situation: each line is one rule over one dataset
Fairmount Funds Management LLC disclosed a 5%+ stake (19.99%) in the last six months.
5 clinical trials were terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Oct 15Fairmount Funds Management LLC filed a 13D for 19.99%
Oct 15Fairmount Healthcare Co-Invest VII L.P. filed a 13D for 19.99%
Oct 15Harwin Peter Evan filed a 13D for 19.99%
Oct 15Kiselak Tomas filed a 13D for 19.99%
Oct 15Fairmount Healthcare Fund II L.P. filed a 13D for 3.98%

Watch TCRT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-21.4%12M
-73%-28%+16%+61%2025-102025-122026-022026-042026-062026-082026-10 2026-10-15 · Fairmount Funds Management LLC filed a 5%+ stake (19.99%)2026-10-15 · Fairmount Healthcare Fund II L.P. filed a 5%+ stake (3.98%)2026-10-15 · Fairmount Healthcare Co-Invest VII L.P. filed a 5%+ stake (19.99%)2026-10-15 · Harwin Peter Evan filed a 5%+ stake (19.99%)2026-10-15 · Kiselak Tomas filed a 5%+ stake (19.99%)
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TCRT: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
21,353 sh
$48.3K
GEODE CAPITAL MANAGEMENT, LLC
19,356 sh
$43.8K
VANGUARD FIDUCIARY TRUST CO
15,497 sh
$35.0K
VANGUARD CAPITAL MANAGEMENT LLC
14,063 sh
$31.8K
CITADEL ADVISORS LLC
11,870 sh
$26.8K

Congress trades in TCRT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Fairmount Funds Management LLC
Activist 13D · 2026-10-15
19.99%
Fairmount Healthcare Fund II L.P.
Activist 13D · 2026-10-15
3.98%
Fairmount Healthcare Co-Invest VII L.P.
Activist 13D · 2026-10-15
19.99%
Harwin Peter Evan
Activist 13D · 2026-10-15
19.99%
Kiselak Tomas
Activist 13D · 2026-10-15
19.99%

TCRT planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

TCRT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$44.5K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$31.8K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$3.3K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$6.8K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$6.9K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
27 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
12
Phase 1
0 active
6
Phase 2
0 active
2
Phase 3
0 active
2
Not applicable
0 active
5
Multi-phase
0 active
What changed recently
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
2026-10-03 · Completed → Terminated · Sponsor business decision: enrollment closed after the Phase 1 dose escalation, before an MTD was reached. The Phase 2 portion was not conducted.
Phase 1
Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors
2026-10-01 · Completion moved 2009-06-11 → 2009-09-29
Phase 1
Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors
2026-10-01 · Completed → Terminated · No dose-limiting toxicity was observed. The sponsor concluded the study after 3 subjects at the higher dose level; the optional 10-subject expansion cohort was not enrolled.
Phase 1
A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Met
2026-10-01 · Completed → Terminated · Sponsor stopped enrollment at 67 of about 100 planned participants after an unplanned interim analysis confirmed the primary PFS endpoint had been reached. Enrolled participants were followed to their PFS endpoint.
Phase 2
A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
2026-10-01 · Completion moved 2008-08-08 → 2008-08-09
Phase 2
A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
2026-10-01 · Completed → Terminated · Study closed after Stage 1 (15 of 40 planned patients treated) due to lack of treatment response; criteria to proceed to Stage 2 were not met.
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

TCRT financials

Revenue growth
-50.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.0K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.00x
long-term 2024-12-31 (18 months older than the period end) plus current 2023-12-31 (30 months older than the period end); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
-185.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-128.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-188.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$5.3M
market value at close 2026-10-26 on 2026-08-14 shares, plus long-term 2024-12-31 (18 months older than the period end) plus current 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$5.0K$10.0K$5.0K$2.9M
Operating income-$4.2M-$4.8M-$34.3M-$35.1M
Net income-$4.2M-$4.7M-$4.7M-$37.7M
EPS (diluted)-2.20-2.92-21.97-2.61
Operating cash flow-$2.9M-$5.0M-$30.1M-$29.2M
Cash$1.4M$1.1M$6.1M$39.1M
Long-term debtn/a$0$0$0
Buybacksn/an/a$0$45.0K
SEC XBRL, fiscal years, as known on 2026-10-28

TCRT Stock Sonar score 5/7 axes

Find similar shapesCompare

TCRT ranks highest on financial health (99th percentile) and risk and compliance (44th), and lowest on profitability (16th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
16
Inputs
  • Return on equity-185.9% · 18 pct, sector of 545
  • Return on assets-128.3% · 18 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-188.2% · 11 pct, sector of 576
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtno debt to cover
Growth
37
Inputs
  • Revenue growth, YoY-50.0% · 20 pct, sector of 505
  • Backlog growth, YoY+0.0% · 54 pct, sector of 40
Institutional and government
23
Inputs
  • Funds adding, latest quarter13 · 23 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
44
Inputs
  • Short interest, % of float+0.8% · 82 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+39.8% · 5 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

TCRT filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 20.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies